Biocure Technology Inc.
Biocure Technology Inc.
Indice CSE:
Devise:
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE.X)
SEDAR Information
Information d'entreprise
Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaTéléphone
604-609-7146Fax
N/ACourriel
[email protected]URL
http://www.biocuretech.comDate d’inscription à la cote
Lundi, mai 10, 2010Relations avec les investisseurs
n/aVérificateur
DMCL Chartered Professional AccountantsCapitalisation
Capitalisation:
94000537Réservé à l'émission:
14510547Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
Communiqués de presse
Bulletins
04/07/2024
2024-0701 - Reprise et Changement de Symbole - Désignation Inactive - Biocure Technology Inc. (CURE)
le 4 juillet/July 2024